KR102505253B1 - 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 - Google Patents

암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 Download PDF

Info

Publication number
KR102505253B1
KR102505253B1 KR1020187032126A KR20187032126A KR102505253B1 KR 102505253 B1 KR102505253 B1 KR 102505253B1 KR 1020187032126 A KR1020187032126 A KR 1020187032126A KR 20187032126 A KR20187032126 A KR 20187032126A KR 102505253 B1 KR102505253 B1 KR 102505253B1
Authority
KR
South Korea
Prior art keywords
dose
agent
hu5f9
priming
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187032126A
Other languages
English (en)
Korean (ko)
Other versions
KR20180134367A (ko
Inventor
어빙 엘. 와이즈먼
마크 피. 차오
라빈드라 마제티
지에 리우
옌스-피터 볼크메어
Original Assignee
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 filed Critical 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Priority to KR1020237006777A priority Critical patent/KR20230035435A/ko
Publication of KR20180134367A publication Critical patent/KR20180134367A/ko
Application granted granted Critical
Publication of KR102505253B1 publication Critical patent/KR102505253B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187032126A 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 Active KR102505253B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237006777A KR20230035435A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US62/323,330 2016-04-15
US201662427679P 2016-11-29 2016-11-29
US62/427,679 2016-11-29
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006777A Division KR20230035435A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Publications (2)

Publication Number Publication Date
KR20180134367A KR20180134367A (ko) 2018-12-18
KR102505253B1 true KR102505253B1 (ko) 2023-03-02

Family

ID=60042716

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187032126A Active KR102505253B1 (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
KR1020247002294A Pending KR20240016445A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
KR1020237006777A Ceased KR20230035435A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247002294A Pending KR20240016445A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
KR1020237006777A Ceased KR20230035435A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Country Status (12)

Country Link
US (3) US11472878B2 (https=)
EP (3) EP3442578B1 (https=)
JP (3) JP7532009B2 (https=)
KR (3) KR102505253B1 (https=)
CN (3) CN109152837A (https=)
AU (2) AU2017250809B2 (https=)
CA (1) CA3019676A1 (https=)
ES (1) ES2909835T3 (https=)
PL (1) PL3442578T3 (https=)
PT (1) PT3442578T (https=)
SI (1) SI3442578T1 (https=)
WO (1) WO2017181033A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
JP7308191B2 (ja) 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７剤ベースの卵巣癌療法
CN111699005A (zh) * 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
JP2021529219A (ja) * 2018-07-05 2021-10-28 トリカン・バイオテクノロジー・カンパニー・リミテッドＴｒｉｃａｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ ヒト抗ｃｄ４７抗体およびその使用
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
EP3886869A4 (en) 2018-11-28 2022-07-06 Forty Seven, Inc. GENETICALLY MODIFIED ABLATION-RESISTANT HSPCS
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
KR20220163447A (ko) * 2020-04-06 2022-12-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체 제형
WO2022076928A1 (en) * 2020-10-09 2022-04-14 Sana Biotechnology, Inc. METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT
US12071481B2 (en) 2020-12-23 2024-08-27 D-10 Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
JP2024503822A (ja) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205280B1 (en) * 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
AU2009210741A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
KR102100388B1 (ko) 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
NZ710695A (en) 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN105143876B (zh) * 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
JP6843611B2 (ja) 2013-04-29 2021-03-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 免疫を強化する抗ｃｄ４７因子の使用
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
WO2015189698A2 (en) * 2014-06-08 2015-12-17 Beijing Cosci-Remd Bio Med Tech Company Ltd Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
EP3204420B1 (en) * 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
KR20220163447A (ko) * 2020-04-06 2022-12-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체 제형

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer

Also Published As

Publication number Publication date
JP7442591B2 (ja) 2024-03-04
US20190106491A1 (en) 2019-04-11
ES2909835T3 (es) 2022-05-10
SI3442578T1 (sl) 2022-05-31
PT3442578T (pt) 2022-05-19
US11472878B2 (en) 2022-10-18
PL3442578T3 (pl) 2022-06-20
CN115350276A (zh) 2022-11-18
JP7532009B2 (ja) 2024-08-13
KR20240016445A (ko) 2024-02-06
JP2024059764A (ja) 2024-05-01
EP4349412A3 (en) 2024-06-12
EP4074339A1 (en) 2022-10-19
US20230068235A1 (en) 2023-03-02
CN109152837A (zh) 2019-01-04
EP3442578B1 (en) 2022-02-09
AU2017250809A1 (en) 2018-10-25
WO2017181033A1 (en) 2017-10-19
AU2017250809B2 (en) 2024-02-29
EP4349412A2 (en) 2024-04-10
EP3442578A1 (en) 2019-02-20
KR20230035435A (ko) 2023-03-13
CA3019676A1 (en) 2017-10-19
US11718670B2 (en) 2023-08-08
AU2024203396A1 (en) 2024-06-06
JP2022172278A (ja) 2022-11-15
JP2019515899A (ja) 2019-06-13
KR20180134367A (ko) 2018-12-18
CN117695387A (zh) 2024-03-15
EP3442578A4 (en) 2019-04-10
US20230406923A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
KR102505253B1 (ko) 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
AU2020264334B2 (en) Targeted therapy for small cell lung cancer
US11891450B2 (en) Anti-CD47 agent-based treatment of CD20-positive cancer
AU2014238105B2 (en) Methods for achieving therapeutically effective doses of anti-CD47 agents
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40108467A (zh) 用於确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
EP3668894A1 (en) Treatment of ck8 positive cancers in relation with k-ras gene status
HK40086849A (en) Anti-cd47 agent-based treatment of cd20-positive cancer
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601